NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance

NEOGENOMICS INC

Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).
Net loss decreased 50% to $19M; Adjusted EBITDA turned positive at $3M vs -$12M YoY.
Raised FY23 revenue guidance to $585-592M (15-16% growth); Adj. EBITDA loss guidance improved to $4M-$1M loss.
Cash and marketable securities $402M at quarter end.
Adjusted Gross Profit Margin 44.2%, excluding amortization of acquired Inivata developed technology intangibles.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

NEOGENOMICS INC reported its third fiscal quarter of 2023 results: revenue $152 million, net income $19 million. Guidance raised.

Period: its third fiscal quarter of 2023
Revenue: $152 million
Net income: $19 million
Guidance: raised
Result: reported results

Exact text from the filing

as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Fort Myers, Florida (November 6, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its third-quarter

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NEOGENOMICS INC filing history →

Source: SEC EDGAR

accession 0001077183-23-000136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.